TY - JOUR T1 - Treatment of hepatitis C, then, now and tomorrow JF - Evidence Based Medicine JO - Evid Based Med SP - 23 LP - 23 DO - 10.1136/ebmed-2014-110103 VL - 20 IS - 1 AU - Richard K Sterling AU - Narayan Dharel Y1 - 2015/02/01 UR - http://ebm.bmj.com/content/20/1/23.abstract N2 - Commentary on: Kohli A, Shaffer A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA 2014;312:631–40.OpenUrlCrossRefPubMedWeb of ScienceHepatitis C virus (HCV) infects over 185 million people worldwide and can lead to progressive liver fibrosis, cirrhosis, hepatocellular carcinoma and death. Antiviral treatment can prevent these complications and improve survival. Interferon has been the backbone of anti-HCV therapy, but has been plagued by side effects, treatment failure and relapse. HCV treatment has seen significant changes with the advent of directly acting antiviral agents with nearly 100% cure rate with all oral, interferon and ribavirin-free regimens.This systematic review of randomised controlled trials (RCTs) and cohort studies aimed to examine the safety, tolerability and efficacy of all Food and Drug Administration (FDA)-approved regimens against HCV genotypes 1, 2 and 3. All studies between January 2009 and May 2014 were included if they were published in English, used FDA-approved antiviral therapies, included sustained virological response (SVR) as the study outcome, and defined treatment … ER -